🔗 Share this article

A shadow market for unlicensed slimming medications is propelled by social media fitness personalities and sellers on communication apps, based on recent findings.

Experimental Treatment Gaining Traction Via Social Media

The experimental drug, which remains in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Followers are urged to contact these profiles directly for source information, while also obtaining promotional offers.

Active Trade on Social Networks

Additionally, a flourishing market exists on messaging services, where groups with thousands of participants share comparison photos, administration instructions and claims of next-day UK delivery. Sellers market the drug there before redirecting buyers to WhatsApp for purchases.

Understanding The Experimental Drug

This medication is an experimental injection created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – GLP-1, GIP and pancreatic hormone. Early trials suggest it could help patients lose up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic.

Healthcare Professionals Express Concerns

However, doctors and pharmacists have cautions that the sale of what is still an unapproved drug in the United Kingdom is a cause for concern and could result in individuals injecting substances of uncertain source.

Several professionals stated the popularity for retatrutide could be linked to the rising price of licensed slimming treatments such as Mounjaro.

Regulatory Position and Implementation

Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved medication that must not be promoted or distributed for human use under the Human Medicines Regulations 2012.

Some influencers try to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but promotion and distribution can still violate medicines, marketing, and customer regulations, risking penalties, prosecution or imprisonment.

Service Response and Material Elimination

According to the social media company, the platform has taken down violative material and prohibited associated keywords and search suggestions. The organization stated it was dedicated to maintaining the platform safe and allocating resources in strengthening enforcement strategies.

Digital Trading Activities

Investigations also found groups with up to 9,000 members selling retatrutide using the platform's integrated search feature, which operates like a online catalog. Typing “retatrutide” instantly displays channels with thousands of users, filled with photos of weight loss, glowing reviews and step-by-step instructions for preparing or administering at home.

Within moments of entering one group, a seller posted contact information, where the majority of purchases take place. The seller sent an instruction manual and promised delivery within 48 hours. When questioned whether the product was authentic, one vendor responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about body mass, medical conditions or past usage.

Item Details and Costs

Within these groups, posts display black plastic parcels with postal service labels, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, mixed at residence with sterile water, or pre-filled injectors usually priced at 160 pounds for 20 milligrams. When asked how much time a injector should be used, vendors give conflicting answers varying between a few weeks to “depends on your body”.

Platform Oversight and Safety Actions

A representative for the messaging service stated it regularly moderated harmful material on its service including content that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are injecting substances they can’t verify. Even if the research behind retatrutide is sound, these online versions may not include what they claim,” said Jason Murphy, the director of pharmacy at a pharmacy service.

A medical professional of Asda Online Doctor connected the surge in demand to current cost increases for approved weight-loss drugs such as Mounjaro. “With costs increasing, individuals are using online platforms. But counterfeit treatments are extremely dangerous. You cannot know what’s inside or whether the conditions they were made in was sterile,” she said.

Her staff has already seen individuals harmed by personal administration from unconfirmed suppliers. “We understand the frustration, but purchasing from Telegram or WhatsApp is taking chances with your health,” said the doctor. “These materials could be contaminated or improperly measured.”

Producer Position

A spokesperson from the pharmaceutical company said retatrutide was in third stage research studies and had not been reviewed or approved by any regulatory agency globally. “Consequently at this point no one can sell [it] for human use,” they said, noting that any product “falsely representing itself as a company investigational product not yet authorized … may subject users to potentially significant health risks”.